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Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) encodes a G protein-coupled receptor (vGPCR) in open reading
frame (ORF) 74, which is homologous to human chemokine receptors. KSHV vGPCR is constitutively active and induces
VEGF-mediated angiogenesis. Previous studies have shown that ORF 74 is transcribed as part of a bicistronic message
containing ORF K14 upstream of ORF 74, with an early lytic pattern of expression. We have now extended these studies by
analyzing three different KSHV-positive primary effusion lymphoma (PEL) cell lines and three PEL clinical samples. In
addition, we have identified another less abundant monocistronic transcript containing only ORF 74. Both transcripts were
identified at low but similar levels in two PEL clinical samples. We evaluated the degree of sequence and functional
conservation of ORF74 in three additional PELs and two KS clinical specimens, demonstrating complete identity at the amino
acid level among all isolates. While it is expressed as an early lytic transcript in PEL cell lines, in primary clinical PEL samples
transcription of KSHV vGPCR can be readily detected. © 2001 Academic Press
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Kaposi’s sarcoma-associated herpesvirus (KSHV) or
human herpes virus 8 (HHV-8) belongs to the family of
g-herpesviruses and is the first member of the rhadino
viruses found to infect humans (Chang et al., 1994;
Moore et al., 1996b). This virus appears to be a neces-
sary, although insufficient, etiologic agent for Kaposi’s
sarcoma (Chang et al., 1994; Moore and Chang, 1995),
primary effusion lymphoma (PEL) (Cesarman et al.,
1995a), and a large fraction of cases of multicentric
Castleman’s disease (Soulier et al., 1995). Sequence
analysis of the entire viral genome has identified more
than 10 open reading frames (ORFs) with cellular homo-
logues (Cesarman et al., 1996; Moore et al., 1996a; Nich-
olas et al., 1997a,b; Russo et al., 1996). Among these,
some might be implicated in tumor induction, as they are
homologous to known cellular oncogenes, and others
have the ability to subvert normal cellular pathways in-
volved in cell cycle regulation (Chang et al., 1996), cell
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62death (Cheng et al., 1997) and/or signal transduction
(Arvanitakis et al., 1997; Gao et al., 1997). One of these is
RF 74, encoding a viral G protein-coupled receptor
vGPCR) that is homologous to cellular chemokine re-
eptors, with the closest homology to the human IL-8
eceptors type A and B (Cesarman et al., 1996). This
eceptor can bind chemokines from the CXC and the CC
amily, but does not require ligand engagement for its
ctivation, having agonist-independent (constitutive) ac-
ivity (Arvanitakis et al., 1997). Bais et al. (1998) demon-
trated that KSHV vGPCR is transforming when trans-
ected into NIH3T3 cells. In addition, and probably more
mportant to the pathogenesis of KS than a direct onco-
enic role, it was shown that signaling by vGPCR even-
ually leads to the upregulation of VEGF expression,
herefore inducing angiogenesis via paracrine mecha-
isms (Bais et al., 1998). A recent study in transgenic
ice has shown that KSHV vGPCR expression in hema-
opoietic cells leads to angioproliferative lesions exhib-
ting remarkable similarity to KS (Yang et al., 2000). In this
odel, KSHV vGPCR was under the control of the CD2
romoter and thus expressed by sparse VEGF-producing
cells infiltrating the vascular lesions. Although T cells
re not thought to be infected by KSHV in vivo, this study
onetheless adds weight to the argument that vGPCR is
n important player in KSHV-mediated disease.
Herpesviruses are able to establish latency, a unique
tage of the viral life cycle during which only a restricted
umber of viral genes are expressed without viral repli-
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63KSHV vGPCR TRANSCRIPTIONcation. Upon acute infection or during the switch from
latency to lytic cycle, a whole array of viral genes are
expressed, resulting finally in the production of viral
particles and the demise of the host cell. There is a
well-defined temporal cascade of the viral transcripts
and proteins during the lytic cycle in herpes viruses. This
sequential expression allows us to classify them as
immediate early (IE or a), early (E or b), and late (L or g)
ranscripts and/or proteins. The analysis of the KSHV-
nfected BCBL-1 cell line demonstrated a restricted pat-
ern of gene expression (Zhong et al., 1996). Subsequent
ranscription mapping divided KSHV transcripts into
hree categories. Class I mRNAs are expressed under
tandard growth conditions and are not inducible by TPA;
lass II transcripts are detectable in variable amount
ithout stimulation, but their expression is significantly
pregulated by TPA-induced lytic replication, and class
II transcripts are only detectable upon TPA treatment
Sarid et al., 1998). More detailed analysis of a fraction of
hese genes has suggested that class II genes in reality
epresent lytic genes abundantly expressed by a small
ubset of cells spontaneously entering the lytic cycle in
EL cell lines (Sun et al., 1999).
Two studies have mapped the transcription of the
SHV vGPCR (Kirshner et al., 1999; Talbot et al., 1999).
Each of these studies used a different single PEL cell
line (BCP-1 and BCBL-1, respectively), and both found
that KSHV vGPCR is transcribed as a 2.7-kb bicistronic
transcript, downstream from ORF K14, with a small intron
in the K14/GPCR intergenic noncoding region. This tran-
script was found to have an early lytic pattern of expres-
sion. The K14/GPCR promoter has been recently
mapped, and transcriptional initiation from this promoter
has been found to be dependent on the immediate early
transactivator ORF 50 (Rta) (Jeong et al., 2001). We have
confirmed and extended these studies by analyzing the
pattern of vGPCR expression in three additional cell lines
and three primary PEL clinical samples. In addition to the
more abundant bicistronic transcript, we identified a
monocistronic transcript that was also seen in two PEL
clinical samples. We also sequenced vGPCR from addi-
tional viral isolates to determine the degree of structural
and functional conservation of this viral receptor likely to
be involved in the pathogenesis of Kaposi’s sarcoma,
primary effusion lymphomas, and multicentric Castle-
man’s disease.
RESULTS
Expression analysis in PEL cell lines
To confirm the pattern of expression of the KSHV
vGPCR gene, Northern blots were performed using
mRNA obtained at several time points from the BC-1,
BC-2, and BC-3 cell lines treated with 12-O-tatrade-
canoylphorbol-13 acetate (TPA), phosphonoformic acid
(PFA, foscarnet), and TPA 1 PFA. mRNAs extracted fromuntreated cell lines were used as controls. The blots
were hybridized to double-stranded probes, as well as a
single-stranded riboprobe for the vGPCR (ORF 74) with
the same results. In addition, filters were hybridized with
probes for the immediate early protein (ORF 57), latent
nuclear antigen (ORF 73), DNA polymerase (ORF 9),
vBCL-2 (ORF 16), K2 (vIL-6), and viral cyclin (ORF 72) for
comparison.
A band of approximately 2.7 kb was detected upon
Northern blot analysis using a vGPCR probe after 10 h of
induction with TPA, and the transcription increased dra-
matically up to 48 h of treatment (Fig. 1). In some exper-
iments the peak amount of transcription was seen at 30 h
of stimulation, dropping between 30 and 48 h. A fainter
band, representing a second transcript of approximately
1.4 kb, also appeared upon TPA induction (Fig. 1). This
band was identifiable in all three cell lines. Both the 2.7-
and 1.4-kb transcripts were identified when a vGPCR
probe was used, but only the larger transcript was seen
when a probe specific for ORF K14 was utilized (Fig. 2).
This observation suggests that the 2.7-kb transcript cor-
responds to the previously reported bicistronic message
(Kirshner et al., 1999; Talbot et al., 1999) and the 1.4-kb
band corresponds to a previously unidentified transcript
coding for vGPCR, but not containing ORF K14 (Fig. 2).
Foscarnet, a viral DNA polymerase inhibitor, did not
abrogate the TPA effect, suggesting that this transcript is
not dependent on viral DNA replication, thus having an
early lytic pattern of gene expression. KSHV vGPCR was
not detectable on Northern blot analysis using total RNA
from untreated cells. However, a faint band at 2.7 kb
FIG. 1. Northern blot analysis of KSHV vGPCR expression in the BC-2
cell line. Poly(A)-selected RNA was prepared from the KSHV-positive
BC-2 PEL cell line after treatment with TPA, PFA, or both. C indicates
mRNA from the untreated BC-2 cell line. The duration of treatment is
indicated in hours above each lane. The mRNA was separated, trans-
ferred, and hybridized with at probe corresponding to ORF74, encoding
vGPCR. A band migrating at around 2.7 kb is seen as early as 10 h after
TPA treatment, but is strong at 20 h and further increased by 48 h. In
addition, a weaker band at around 1.4 kb can be identified after 30 h of
treatment with TPA. The 2.5- and 1.5-kb bands are indicated by arrows.
Neither transcript could be inhibited by treatment with PFA, suggesting
an early lytic pattern of expression. The lower panel shows hybridiza-
tion of the same filter with a b-actin probe, demonstrating similar
amounts of mRNA in all lanes.could be appreciated by Northern blot analysis of the
64 NADOR ET AL.poly(A)-selected RNA fraction in some experiments but
not in others. This signal did not disappear upon foscar-
net treatment alone for up to 48 h (not shown). The viral
DNA polymerase expression exhibited the expected
early lytic pattern, although its expression was delayed
as compared to the vGPCR, appearing between 20 and
30 h of induction with TPA, and was not inhibited by PFA.
The vIL-6 and vBCL-2 (not shown) exhibited a similar
pattern to vGPCR, except that these transcripts were
more obviously detectable in the unstimulated cell lines.
Since the distinction of immediate early lytic from early
lytic gene expression has been made based on the
requirement for previous viral protein synthesis in the
latter, we treated the cells with TPA in conjunction with
cycloheximide (Fig. 3). While the TPA-induced expres-
sion was significantly decreased, it was not completely
abolished by cycloheximide. The pattern was similar to
that of ORF57, which is a homolog of ORF 57 and BMLF1,
immediate early genes of herpesvirus saimiri and Ep-
stein–Barr virus (EBV/HHV-4), respectively. However, the
vGPCR band was fainter than that of ORF57 upon TPA
and cycloheximide treatment, so this profile is most con-
sistent with an early lytic pattern of expression. In con-
trast, latent nuclear antigen (LNA) mRNA transcription is
not inducible by TPA and its synthesis is not affected by
cycloheximide, as expected for a latent gene.
The variable presence of low levels of vGPCR tran-
scription in uninduced cultures suggested that these
transcripts may originate in a small proportion of lytic
cells and that the proportion of these cells is dependent
on culture conditions. To confirm this, we performed
FIG. 2. Northern blot analysis using a KSHV vGPCR or K14 probe in
the BC-2 cell line. Poly(A)-selected RNA was prepared from the BC-2
PEL cell line after treatment with TPA, followed by Northern blotting and
hybridization with an ORF 74 probe (GPCR, left) or K14 probe (right), as
indicated. While the more intense band at 2.7 kb was detected by both
probes, the weaker band at 1.4 kb was only detected when the ORF 74
probe was used, even after long exposure, indicating that the large
transcript is bicistronic, while the smaller transcript is a monocistronic
mRNA encoding KSHV vGPCR.immunofluorescence staining of the untreated cell lineswith a monoclonal antibody to ORF 59, encoding a DNA
replication protein (Ruby Chan et al., 1998). We could
achieve an “almost” complete latency (,0.1% positive
cells) by maintaining rigorous cell culture conditions,
including careful monitoring of cell concentration and the
frequent addition of fresh media. We performed RT-PCR
in these cultures to evaluate whether low levels of vG-
PCR message could be detected and compared this
result to that of other early lytic transcripts. A represen-
tative experiment using the BC-3 cell line is shown in Fig.
4. We could always detect a signal using the vGPCR
primer set, which was also the case for ORF 57. In
contrast, no transcription could be identified in untreated
cells when using primers for two early lytic genes, a DNA
replicase (ORF 59) and a DNA polymerase (ORF 9). Thus,
transcription of the KSHV vGPCR may be due to a small
percentage of cells undergoing abortive replication, or to
“leaky” expression of very low levels in a larger propor-
tion of latent cells. In contrast, viral IL-6 was expressed
at significant levels, despite tight latency (Fig. 4). This
result has been confirmed by immunofluorescence of
tightly latent cell cultures with a polyclonal rabbit anti-
serum to the viral IL-6, where 20–40% of the cells were
positive (Hyjek and Cesarman, unpublished observa-
tion). This result suggests that viral IL-6 is being tran-
scribed at higher levels and/or by a larger proportion of
cells than vGPCR and ORF 57 and may be considered a
partially latent gene in PELs.
Finally, no significant difference could be demon-
strated between the double-infected (EBV and KSHV)
BC-1 and BC-2 cell lines and the KSHV-only infected
FIG. 3. Northern blot analysis of KSHV gene expression in BC-3 cells.
Poly(A)-selected RNA was prepared from the BC-3 PEL cell line after
treatment with TPA and TPA plus cycloheximide (CYC). C indicates
mRNA from the untreated BC-2 cell line. The duration of treatment is
indicated in hours above each lane. The mRNA was separated, trans-
ferred, and hybridized with probes for KSHV ORF74 (GPCR), ORF 57,
and LNA. The pattern of expression of vGPCR and ORF 57, considered
an immediate early gene, was similar, with induction by TPA and partial
inhibition in the presence of cycloheximide, a protein synthesis inhib-
itor. Transcription of LNA, a latent gene, was not inhibited by cyclohex-
imide. The lower panel shows hybridization of the same filter with a
b-actin probe, demonstrating similar amounts of mRNA in all lanes.
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65KSHV vGPCR TRANSCRIPTIONBC-3 cell line. However, we observed that it was easier
to achieve a complete latent stage with undetectable
vGPCR transcription by Northern blot analyses in the
BC-2 cell line than in BC-3, where the low level of tran-
scription was more persistent.
Expression of KSHV vGPCR in PEL clinical specimens
vGPCR is readily detectable by RT-PCR analysis in PEL
clinical samples (Cesarman et al., 1996). To determine
hether vGPCR is expressed in vivo in PELs at detect-
ble levels similar to the uninduced PEL cell lines, we
xtracted mRNA from three PEL clinical samples. North-
rn blot analysis revealed the presence of two faint but
istinct bands corresponding to the monocistronic and
icistronic transcripts detected in the cell lines (2.7 and
.4 kb, respectively) in two of these specimens (Fig. 5).
herefore, this gene is transcribed in vivo at low but
ignificant levels in the primarily latently infected tumor
FIG. 4. RT-PCR analysis for latent and lytic gene expression in BC-3
cells. Total RNA was prepared from the BC-3 PEL cell line, following
careful culturing and monitoring for lytic viral replication. The experi-
ment shown is using cells in which less than 0.1% of cells were
expressing a lytic antigen (ORF 59). Untreated cells (U) were compared
to TPA or TPA plus PFA (P)-treated cells. A KSHV-negative cell line
(BJAB) was used as a negative control (N), and water was used to test
for contamination (W). DNase treatment and reverse transcription were
performed, followed by PCR using primers for the indicated viral gene
products. These reactions were also performed using RNA in the
absence of a reverse transcription step to exclude viral DNA as a
template for amplification (not shown). This experiment shows that ORF
74 (GPCR) and ORF 57 (IE protein) transcripts could always be de-
tected, albeit at very low levels, in the latent cultures, while transcripts
for other lytic genes (ORF 59 and 9) could not. Expression of a latent
gene (vCyclin) was seen in untreated cultures and so could expression
of the vIL-6, considered a Type II, or early lytic transcript. While RT-PCR
is only semiquantitative and is not quantitative at high or saturating
levels of template, these results indicate that despite a tight latency, as
reflected by a complete lack of amplification of true lytic transcripts,
clear expression of vIL-6 and low expression of vGPCR can be appre-
ciated.ells.Cloning of KSHV vGPCR mRNA
We sequenced a total of 17 clones obtained from a
cDNA library from TPA-treated BC-1 cells, out of which 13
were considered full length as they were confirmed by at
least one additional clone with an identical 59 end. A
schematic representation of these clones is shown in
Fig. 6, and the full sequence is provided in Fig. 7. Eleven
of these clones had a full-length, polyadenylated cDNA
that was 2700 bp in length, corresponding to the larger
transcript seen by Northern blot analysis (identified as
FIG. 5. Northern blot analysis for KSHV vGPCR in three primary
effusion lymphomas. Poly(A)-selected RNA was prepared from three
clinical samples obtained from pleural or peritoneal effusions during
diagnostic procedures, followed by Northern blotting and hybridization
with a probe for ORF 74 (GPCR). As a control, mRNA from TPA-treated
BC-2 cells was used (C). Two bands of approximately equal intensity
were detected in samples 2 and 3, corresponding in size to the
monocistronic and bicistronic vGPCR transcripts. This result suggests
that this gene is transcribed in significant amounts in vivo. The lower
panel shows hybridization of the same filter with a b-actin probe,
demonstrating similar amounts of mRNA in all lanes.
FIG. 6. Map of the different KSHV vGPCR transcripts. A schematic
representation of the genomic map and different clones obtained from
a cDNA library of BC-1 cells is provided. Three different types of clones
were identified: (1) a 2.64-kb bicistronic clone containing ORF K14 and
ORF 74; (2) a 2.5-kb bicistronic clone, with a spliced 149-bp fragment
within the untranslated region, located 3-bp upstream from the ORF74
initiation site; (3) a 1.42-bp clone, which is identically spliced, but
initiates within the untranslated region and lacks ORF K14. The number
of each of these clones obtained after screening the cDNA library is
indicated in the figure.
66 NADOR ET AL.FIG. 7. Nucleic acid and translated sequence of cDNA clones containing vGPCR. The sequence of three representative clones is provided. cDNA
A is an unspliced bicistronic transcript containing ORF K14 (Ox-2) and ORF 74 (vGPCR) and is representative of eight similar clones. cDNA B is a
spliced transcript containing ORF K14 (Ox-2) and ORF 74 (vGPCR) and is representative of three clones. cDNA C is a spliced transcript containing
ORF 74 (vGPCR), initiating at position 1070 of the larger transcript, and is representative of two identical clones. Four clones were found to lack the
first two bases from cDNAs A or B, but no additional clones were identified with initiation sites other than the ones indicated. Underlined bases within
ORF 74 at positions 2057, 2111, and 2441 indicate polymorphisms in other cases of KS and PEL examined. Dashes (–) represent identities and X’s
represent deletions (intronic sequence).
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67KSHV vGPCR TRANSCRIPTIONcDNAs A and B in Fig. 7). This message contained the
ORF K14 upstream of ORF 74, with a 442-bp-long un-
translated region (UTR) between the two ORFs. Two
smaller polyadenylated cDNA clones with a size of 1480
bp were also identified (cDNA C in Fig. 7), corresponding
to the smaller band seen by Northern blot analysis of the
TPA-treated PEL cell lines and the PEL specimens.
These two clones represent a monocistronic mRNA with
a 298-bp untranslated region 59 of ORF 74. Three of the
bicistronic clones and the two monocistronic ones were
spliced within the UTR (cDNAs B and C, respectively).
The splice donor and acceptor nucleotide sequences
were identified. The spliced intron is 149 bp long, located
3 bp upstream from the ORF74 initiation site. We per-
formed an RT-PCR assay using primers flanking the
spliced fragment to determine whether both spliced and
unspliced transcripts were present in KS and PEL tis-
sues in vivo. The presence of both large and small forms
was identified, confirming the presence of both types of
transcript in lesional tissues (data not shown). A Kozak
consensus sequence (Kozak, 1989), which is important
for an efficient translation by eukaryotic ribosomes, was
identified around the ORF 74 initiation sites, but this
consensus sequence is not present in the initiation re-
gion of ORF K14, suggesting that translation of the down-
stream ORF 74 may be more efficient.
Functional and structural conservation
To evaluate the structural conservation of vGPCR
among different viral isolates, we PCR-cloned this gene
from two KS biopsies, two PEL specimens, and one PEL
cell line (BC-3). Alignment of the five sequences against
our published prototype sequence from BC-1 cells (Ce-
sarman et al., 1996; Russo et al., 1996) and the sequence
f the CDNA clones showed two single nucleotide sub-
titutions at nucleotide positions 2057 (A3 G) and 2441
G3 T) of ORF74 in all five specimens (underlined in Fig.
7). One additional single nucleotide substitution at posi-
tion 2111 (C3 T) was identified in one KS and the two KS
specimens. However, none of these nucleotide varia-
tions brought about any changes at the level of the amino
acid sequence, which was identical to that of our proto-
type clone. Representative clones from each of the dif-
ferent specimens above were assayed for their ability to
activate signal transduction by measuring the accumu-
lation of intracellular second messengers (inositol phos-
phates, InsP) in COS-1 cells transiently transfected with
the respective expression vectors as previously de-
scribed (Arvanitakis et al., 1997). As expected from the
lack of amino acid sequence variations, all the clones
analyzed exhibited agonist-independent activity, as evi-
denced by the accumulation of inositol phosphates in the
absence of exogenous ligand (data not shown).DISCUSSION
The ORF 74 of KSHV encodes for a G protein-coupled
receptor with homology to chemokine receptors. KSHV
vGPCR has been demonstrated to have agonist indepen-
dent-activity, transducing signals that result in angio-
genic and oncogenic effects and therefore likely involved
in the pathogenesis of KSHV-related malignancies. Here
we report that, as previously demonstrated, vGPCR ex-
hibits the kinetics of an early lytic protein and is primarily
transcribed as a 2.7-kb bicistronic message. However, in
addition, we identified a smaller 1.4-kb mRNA by North-
ern blot analysis and as an underrepresented clone
upon cDNA library screening.
As no satisfactory antibodies are available to evaluate
vGPCR protein expression, we can only deduct the pat-
tern of expression of this gene product from the tran-
scriptional pattern. The most abundant transcript con-
tains the K14 ORF upstream from ORF 74, suggesting that
translation of the former may be more efficient. In this
context, it would be possible that the sparse monocis-
tronic transcript is the main source of vGPCR protein in
PEL cells. However, the presence of the Kozak consen-
sus sequences only around the ORF 74 initiation codon
might suggest that vGPCR is more readily translated by
the translation machinery than the K14. Ongoing exper-
iments in our laboratory are aimed at evaluating the
translational efficiency of the different transcripts.
Our experiments with TPA and PFA clearly demon-
strated that vGPCR is inducible and the transcription is
not affected by a viral DNA polymerase inhibitor. There-
fore, this viral gene fulfills the criteria for an early lytic
gene. KSHV vGPCR is always present, although at min-
imal level in latent cell cultures, and increased level of
transcription is detectable earlier than for other typical
early genes (e.g., ORF 56 and 59) during induction of the
lytic cycle. Therefore, we evaluated whether vGPCR
could be an immediate early gene. In PEL cell lines
cycloheximide treatment greatly inhibited the TPA-in-
duced accumulation of the vGPCR transcript, suggesting
that it is an early transcript. However, ORF 57, which
shows sequence homology to BMLF1, an EBV immediate
early gene, exhibited similar kinetics in that transcripts
were reduced but not abolished. While the significance
of a very small residual signal after cycloheximide treat-
ment is unclear, and it is difficult to draw definitive
conclusions, our findings and those of others are most
consistent with vGPCR having an early lytic pattern of
expression.
The bicistronic and the monocistronic vGPCR tran-
scripts could be also detected in primary effusion lym-
phoma specimens by Northern blot analysis, corroborat-
ing expression in vivo. While PELs are mainly latently
infected by KSHV, a few cells switching to the lytic cycle
are almost invariably present. Moreover, while Northern
blots failed to detect vGPCR transcripts in the strictly
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68 NADOR ET AL.maintained PEL cell lines, transcription of this gene was
always readily demonstrable by RT-PCR analysis. We
could quantitate the number of cells switching to viral
replication by immunofluorescence using an antibody to
a lytic antigen (ORF59) and found it to vary from 0 to 1%
in carefully maintained cultures. It has been previously
suggested that the detection of early lytic genes during
latency may be due to cells switching to lytic cycle (Sun
et al., 1999). Our results show that while this may be true
for some transcripts, such as DNA replicase (ORF 59)
and DNA polymerase (ORF 9), the explanation may be
more complex for others. In particular, expression of
vIL-6 and vBCL-2 remains relatively high in the tightly
latent cultures, suggesting that these genes can either
be latently expressed or that an abortive or leaky lytic
cycle can occur with expression of selected early lytic
genes. Similarly, low-level transcription expression of
vGPCR could always be detected. An important issue
that remains to be addressed is whether in vivo vGPCR
is expressed at extremely low levels by a significant
proportion of cells or whether the detected transcripts
stem from a very small proportion of infected cells. While
most available evidence suggests the latter, including a
study using in situ hybridization (Kirshner et al., 1999), a
definitive answer to this question will only come with the
development of very sensitive and specific antibodies to
this viral receptor.
In this study we have also investigated the degree of
structural and functional conservation of KSHV vGPCR
from different viral isolates. We have found a complete
amino acid sequence identity in all the viral isolates we
obtained from both PEL and KS. This sequence conser-
vation corresponds to functional conservation, as deter-
mined by agonist-independent signal transduction. Our
results imply that the previously reported transforming
and angiogenic properties of this viral receptor are not
particular to the prototype clone originally examined.
In conclusion, KSHV vGPCR is highly conserved, is
transcribed as a major bicistronic or a rare monocis-
tronic mRNA, and has an untranslated region 59 to ORF74
which may or may not be spliced. Both monocistronic
and bicistronic transcripts exhibit kinetics of expression
which are consistent with an early lytic pattern. Our
observations suggest that a complex program of viral
gene transcription occurs in KSHV-infected cells, with
significant early gene production during latency. The
results presented here, as well as those of others, are
based on the reactivation of the latent KSHV, so acute
infection studies are necessary to further refine the
KSHV viral cycle. Finally, the high degree of conservation
suggests that the vGPCR has an important function in the
life cycle of KSHV. In this study we demonstrate that
vGPCR transcripts are present in PEL tumor samples,
strengthening its candidacy as a viral oncogene impli-
cated in the pathogenesis of KS and PEL. The constant
low level of expression in latently infected cells may besufficient to induce signaling leading to activation of
MAP and PI-3 kinases (Bais et al., 1998; Montaner et al.,
2001) and activating expression of a variety of cellular
genes, which in turn can promote cellular proliferative
and/or inflammatory responses.
MATERIALS AND METHODS
Cell culture
KSHV-positive BC-1, BC-2, and BC-3 PEL cell lines
were established in our laboratory and were cultured
under previously reported conditions (Arvanitakis et al.,
1996; Cesarman et al., 1995b). To stimulate viral replica-
tion, the cell lines were treated with 20 ng/ml of TPA
(Sigma Chemical Co., St. Louis, MO). Foscarnet (Sigma)
was used to inhibit viral replication at the concentration
of 0.5 mM alone or in combination with TPA (20 ng/ml). To
inhibit protein synthesis, the cell cultures were treated
with 50 mg/ml cycloheximide (CYC; Sigma) or with CYC
50 mg/ml) and TPA (20 ng/ml).
athologic samples
Three malignant lymphomatous effusions occurring in
he absence of a clinically identifiable contiguous tumor
ass were selected from among neoplasms acces-
ioned in the Hematopathology Laboratory of the New
ork Presbyterian Hospital–Weill Medical College of Cor-
ell University. Two of these were from pleural effusions,
nd the third patient presented with ascites. The pres-
nce of KSHV was confirmed by Southern blot analysis
s described (Cesarman et al., 1995a).
otal RNA and mRNA extraction
Cells were harvested for RNA extraction after 10, 20,
0, and 48 h of treatment or after 6 and 12 h for the
ycloheximide experiments. Total RNA was extracted
ith the RNAZOL solution (GIBCO–BRL Life Technolo-
ies, Baltimore, MD) according to the manufacturer’s
nstructions. Poly(A1)-selected RNA was isolated with
he PolyATract mRNA Isolation System (Promega Corp.,
adison, WI). RNA samples were treated with 2 U of
Nase-free DNase I (Boehringer-Mannheim, Indianapo-
is, IN) before the Northern blot and RT-PCR analyses.
orthern blot analyses
Aliquots (800 ng) of poly(A)-selected RNA from each
ime-course point were separated electrophoretically in
.5% denaturing formaldehyde agarose gel and blotted
nto nylon filters (DuPont, Boston, MA). After fixation, the
lots were subjected to hybridization to riboprobes or
lternatively, PCR-generated double-stranded DNA
robes that had been 32P-labeled by the random primer
extension method. Then washing of the filters and auto-
radiography was performed according to methods re-
ported previously.
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A 1235-bp-long NcoI fragment containing vGPCR
was cloned into a pcDNA3.1(2) vector (Invitrogen, San
Diego, CA). The amplified fragments of the ORF 72
(cyclin): the ORF 73 (LNA), the ORF 57 (immediate
early protein), the ORF 9 (DNA polymerase), ORF 16
(BCL-2), and K2 (IL-6) were cloned into the pGEM-EZ
vector. The orientation of the inserts was checked by
enzymatic digestion and sequence analysis of the
clones. Riboprobes were synthesized using the T7 or
SP6 RNA polymerases with the Riboprobe Combina-
tion System Kit (Promega) following the manufacturer’s
instructions. Alternatively, the double-stranded PCR
products were used as probes after purification
with the PCR Purification System (Qiagen Inc., Chats-
worth, CA).
Primers, oligonucleotide probes, and PCR conditions
The conditions of the PCRs and the RT-PCRs have
been described in detail elsewhere (Cesarman et al.,
1996). The viral cyclin, vGPCR, and LNA genes were
amplified by utilizing primers from published se-
quences (Cesarman et al., 1996). The following se-
uences of primers were used for amplifying ORF 57
immediate early protein): 59-GACCAGCCGCCATAAT-
AAG-39 and 59-GCTTGACCTCGCCAAGAAGG-39; ORF
(DNA polymerase): 59-GGCTAAGCAATGCCTCGGT-39
59), 59-CTGATCTGTTGGCCGTCCGTC-39 (39), 59-
AGCCAAGCTGGCCAAGATCC-39 (probe); ORF 56 (DNA
replicase): 59-CAATGCTTCAGGACGGC-39 (59), 59-
GATGTCGAGTATGGCCTCAC-39 (39), 59-GCTGCCAA-
CACTGAAGGAAC-39 (probe); K2 (vIL-6): 59-GAGTCAC-
GTCTGGGATAGAG-39 (59), 59-GACGTCATGGAGCT-
TCTGAC-39 (39), 59-CACGCACCGCTTGACCTGC-39
(probe); and ORF59 (DNA replication protein): 59-
CAATGCTTCAGGAAGACGGC-39 and 59-GATGTCGAG-
TATGGCCTCAC-39.
cDNA library and clone sequencing
The cDNA library was constructed from the TPA-
treated BC-1 cell line using the ZAP-cDNA Gigapack III
Gold Cloning System (Stratagene, La Jolla, CA) and
screened with a double-stranded vGPCR probe. A total of
17 clones were purified. Sequencing of both strands was
performed with a Taq DyeDeoxy Terminator Cycle Se-
quencing method with an ABI 373A automated DNA
sequencer (Applied Biosystems, Foster City, CA). The
sequence of representative clones from the three types
of transcript (bicistronic unspliced, bicistronic spliced,
and monocistronic) have been submitted to GenBank
and have received Accession Nos. AF367765, AF367766,
and AF367767, respectively.Cloning and sequencing of KSHV vGPCR from
independent isolates
Cloning of vGPCR from two KS biopsies, two PEL
specimens, and one PEL cell line was performed by PCR
using primers designed to amplify the entire ORF 74 and
flanking sequences as in the previously characterized
clone (Arvanitakis et al., 1997). The primers used were
ggaattccgcagatCAT-GGCGGCCGAGGATT (GR-5a) and
gcgaaggccttCATGGCGTTCCAGTCAATCTACC (GR-3a),
where vGPCR ORF sequences are capitalized. The am-
plified PCR fragment was then subcloned into the
pcDNA3.1 (Invitrogen) eukaryotic expression vector.
Three or four clones were generated from each of the
five specimens, and both strands of each clone were
sequenced. While some of the clones contained substi-
tutions that were not seen in the other clones from the
same specimen, these were interpreted as arising from
DNA polymerase errors rather than indicating true viral
strain variation. The overall error rate calculated on the
basis of our sequence data was 0.20%, which translates
into a variation of 2 bases/kb from PCR. Given the length
of the PCR fragment (1264 bp), this level of error is safely
offset by sequencing three clones from each specimen.
KSHV vGPCR signaling
Representative clones from each of the different iso-
lates were assayed for their ability to activate signal
transduction by measuring the accumulation of intracel-
lular second messengers (InsP) in COS-1 cells tran-
siently transfected with the respective expression vec-
tors as previously described (Arvanitakis et al., 1997).
Twenty-four hours after transfection, cells were collected
and reseeded in DMEM with 10% Nu serum and 1 mCi/ml
myo-[3H]inositol (NEN, Boston, MA) and the culture was
aintained for an additional 24 h. After rinsing, the cells
ere incubated in HBSS containing 25 mM HEPES, pH
.4, with 10 mM LiCl in the absence or presence of
uman recombinant IL-8 (R&D Systems, Minneapolis,
N) at 0.25 mg/ml. Cells were collected after 90 min or
ther time points and accumulated InsP was measured
sing ion-exchange chromatography. Inositol phosphate
ccumulation was calculated as [3H]InsPs/[3H]lipids 1
3H]InsPs.
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